What insurance policy changes affect code D56.1?

There are 11 tracked policy changes affecting code D56.1, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D56.1?

Payers that have issued tracked updates for code D56.1 include: Aetna, Independence Blue Cross.

How do I get notified when code D56.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D56.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D56.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

D56.1 Insurance Policy Changes

ICD-10 D56.1 is officially defined as "Beta thalassemia." code D56.1 is referenced in 11 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D56.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 6, 2026Medium impact
Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-09-25)
Aetna considers non-myeloablative hematopoietic cell transplantation (mini-allograft) medically necessary for members with acute lymphoblastic leukemia, acute myelogenous leukemia, aplastic anemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's disease, multiple myeloma, myelofibrosis, myelodysplasia, neuroblastoma, non-Hodgkin's lymphoma, sickle cell anemia or thalassemia major, where conventional allogeneic transplant is an established alternative. Aetna considers it experimental, investigational, or unproven for acquired angioedema, autoimmune diseases, breast cancer, essential thrombocythemia and polycythemia vera, melanoma, ovarian cancer, renal cancer and testicular cancer. For members with the listed diseases who are eligible for conventional ASCT, mini-allograft is a technical variation of an established procedure; for members who are ineligible for conventional ASCT, including those with other malignancies, mini-allograft is still considered investigational.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2026-09-18)
Aetna's Clinical Policy Bulletin 0626 considers allogeneic hematopoietic cell transplantation medically necessary for thalassemia major and sickle cell anemia in children or young adults when the member meets the transplanting institution's written eligibility criteria. Where no such criteria exist, Aetna considers it medically necessary for thalassemia major in children or young adults with a haploidentical or HLA-matched donor, and for sickle cell anemia when the member has a haploidentical or HLA-matched donor and either a history of stroke or an increased risk of stroke or end-organ damage. Autologous transplant for thalassemia major or sickle cell anemia in children or young adults, treosulfan-based T-cell depleted haploidentical transplant for sickle cell disease or transfusion-dependent thalassemia, and use of T-lymphocyte subsets at engraftment to predict acute graft-versus-host disease risk are considered experimental, investigational or unproven.
Aetna · Identified Aug 19, 2026Medium impact
Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-02-25)
Aetna considers non-myeloablative hematopoietic cell transplantation (mini-allograft) medically necessary for acute lymphoblastic leukemia, acute myelogenous leukemia, aplastic anemia including paroxysmal nocturnal hemoglobinuria, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's disease, multiple myeloma, myelofibrosis, myelodysplasia, neuroblastoma, non-Hodgkin's lymphoma, sickle cell anemia and thalassemia major, for diseases where conventional allogeneic hematopoietic cell transplantation is an established alternative. Aetna considers it experimental, investigational or unproven for acquired angioedema, autoimmune diseases, breast cancer, essential thrombocythemia and polycythemia vera, melanoma, ovarian cancer, renal cancer and testicular cancer. For patients eligible for conventional ASCT, mini-allograft is a technical variation of an established procedure, while for patients who are ineligible for conventional ASCT it is still considered an investigational procedure.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2025-09-25)
Aetna's Clinical Policy Bulletin 0626 covers allogeneic hematopoietic cell transplantation (HCT) for thalassemia major and sickle cell anemia. Aetna considers allogeneic HCT medically necessary for thalassemia major in children or young adults (to age 45 years) when the member meets the transplanting institution's written eligibility criteria, and in the absence of such criteria when a haploidentical or HLA-matched donor is used. For sickle cell anemia in children or young adults, allogeneic HCT is medically necessary when the member meets the transplanting institution's written eligibility criteria, and in the absence of such criteria when the member has a haploidentical or HLA-matched donor and either a history of stroke or an increased risk of stroke or end-organ damage. Autologous HCT for these conditions, treosulfan-based T-cell depleted haplo-identical stem cell transplantation for sickle cell disease or transfusion-dependent thalassemia, and use of T-lymphocyte subsets at engraftment to predict the risk of acute graft-versus-host disease in thalassemia major are considered experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Strontium Chloride Sr-89 (CPB 0361, reviewed 2026-01-09)
Aetna considers strontium chloride Sr-89 medically necessary for the relief of bone pain when the member has a cancer diagnosis and bone metastases. Aetna considers all other indications experimental, investigational, or unproven, including use in members with cancer not involving the bone. Continued therapy on reauthorization is medically necessary when there is no evidence of unacceptable toxicity on the current regimen and the member is experiencing clinical benefit.
Aetna · Identified Aug 16, 2026Medium impact
Luspatercept-aamt (Reblozyl) (CPB 0963, reviewed 2026-06-12)
Aetna's commercial medical plans cover luspatercept-aamt (Reblozyl) as medically necessary for anemia with beta thalassemia and for anemia of myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm, when the criteria in the policy are met, and precertification is required. Aetna considers all other indications experimental, investigational, or unproven, and considers continuation of therapy medically necessary when the member has achieved or maintained a reduction in red blood cell transfusion burden and has not experienced an unacceptable toxicity from Reblozyl.
Aetna · Identified Aug 13, 2026Medium impact
Exagamglogene Autotemcel (Casgevy) (CPB 1052, reviewed 2025-12-31)
Aetna's Clinical Policy Bulletin 1052 covers Casgevy (exagamglogene autotemcel) as a one-time single-dose intravenous infusion for sickle cell disease or transfusion-dependent beta thalassemia when the member meets the listed criteria, and the drug receives dedicated GCIT review for Commercial and Medicare lines of business. Precertification is required for all Aetna participating providers and members in applicable plan designs. The criteria cover members 12 or older with a confirmed genotype, a history of severe vaso-occlusive episodes or transfusion needs, eligibility for stem cell transplant without a matched 10/10 HLA-related donor, and for sickle cell disease, an inadequate response, intolerance or contraindication to hydroxyurea. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)
Aetna's clinical policy for Zynteglo (betibeglogene autotemcel) applies to commercial medical plans, where Aetna's GCIT team gives it dedicated review, and precertification is required for all Aetna participating providers and members in applicable plan designs. Zynteglo is medically necessary as a single-dose treatment for transfusion-dependent beta-thalassemia in members 4 years of age or older who meet the listed criteria, including a genotype confirmed through genetic testing, a regular transfusion history, and eligibility for a hematopoietic stem cell transplant (HSCT) without a matched donor. Aetna considers all other indications experimental, investigational, or unproven, and members who have had a prior HSCT or any prior gene therapy do not meet the initial approval criteria.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with no substantive changes to coverage criteria. The policy continues to cover this gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity requirements. No billing or documentation workflow changes are required.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
This is a reissue of Independence Blue Cross policy 08.02.14a with no substantive changes to coverage criteria for Casgevy (exagamglogene autotemcel), a gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients 12 years and older. The policy maintains existing medical necessity requirements, including prior treatment attempts, documented severe vaso-occlusive crises, and eligibility criteria. Billing teams should verify this reissue does not affect current claim processing but confirm HCPCS code J3392 remains the appropriate billing code.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with NO CONTENT CHANGES on 07/01/2025. This is an informational reissue confirming continued coverage for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity criteria. No billing workflow changes are required.

Watch D56.1

Get one email when a payer policy names D56.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-09-25)

Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2026-09-18)

Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-02-25)

Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2025-09-25)

Strontium Chloride Sr-89 (CPB 0361, reviewed 2026-01-09)

Luspatercept-aamt (Reblozyl) (CPB 0963, reviewed 2026-06-12)

Exagamglogene Autotemcel (Casgevy) (CPB 1052, reviewed 2025-12-31)

Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

What insurance policy changes affect code D56.1?

Which payers have updated policy for code D56.1?

How do I get notified when code D56.1 policy changes?

Why do payers change policies for code D56.1?